The combination of buprenorphine and naloxone (Suboxone) has become a popular replacement therapy for heroin dependence. However, it’s not yet clear how effective it is for prescription opioid dependence, or whether adjunctive counseling provides any additional benefit over the drug alone.

“Self-management” is a newly popular buzzword among clinicians treating the seriously mentally ill.

For years, we have read articles about the promise of pharmacogenetic testing to help us choose and monitor medication treatment.

We know that the postpartum period is a risky time for women who have a history of depression, especially if they experienced postpartum depression in the past. But several questions about mood and pregnancy are still unanswered.

It has been over a year now since the approval of vilazodone (Viibryd). As you may recall from our review of the drug in TCPR April 2011, vilazodone is an SSRI with partial agonism at the 5HT1A receptor.

Common sense dictates that genetic predispositions probably interact with life stressors to influence our mental health. Plenty of research has been published to evaluate whether this is actually true, but findings have been mixed.

Whether you see your patients quarterly, monthly, or even weekly, you certainly are not with them as much as their cell phones are.

Two recent meta-analyses compared second-generation antidepressants (SGADs) to each other regarding efficacy and safety.

We’ve all been told from time to time that we should mind our manners. A Boston psychiatrist, Michael Kahn, suggests that manners are not limited to dinner parties; rather, he calls for “etiquette based medicine.”